Pfizer Releases New Dosage for Sutent Patients
Sutent 37.5 mg Ease of use and lower costs may be on the horizon for Sutent patients who are currently on a 37.5 milligram prescription. Available now, Pfizer has released a new [...]
Sutent 37.5 mg Ease of use and lower costs may be on the horizon for Sutent patients who are currently on a 37.5 milligram prescription. Available now, Pfizer has released a new [...]
The Life Raft Group, in partnership with the National Institutes of Health, is pleased to announce that applications are currently being accepted for the second meeting of the NIH-LRG Virtual GIST Tumor Board.
Charlie Burke has developed a thick skin when it comes to cancer. After surviving bouts with colorectal, thyroid and skin cancers, he was well acquainted with the routine of doctor’s appointments, hospital visits, surgeries and regular treatment that accompany disease by the time a GIST tumor was discovered in his colon. However, as any of our members will tell you, GIST comes with its own unique lexicon to master and set of challenges to overcome.
The 12th Pediatric and Wildtype GIST Clinic was held May 21 to 23, 2014 at the National Institutes of Health in Bethesda, Maryland. Coordinated by Dr. Sosipatros Boikos, and based out of the NIH Pediatric Oncology Department under the direction of Dr. Lee Helman, the Clinic is collaboration between clinicians and researchers to collect data, investigate and develop treatment for GIST patients who do not have either c-KIT or PDGFRA mutation.
Approximately less than one minute into talking with Mariel and Terrance Pridmore, one thing became very clear—they cannot wait to go back to camp.